news

U.S. Representatives Debbie Dingell (D-MI-06) and Bob Latta (R-OH-05) introduced the bipartisan Biomanufacturing Excellence, Domestic Resilience, Output, and Competitive Know-how Act, or the BEDROCK Act. This legislation would help turn products invented in America into products made in America—supporting American manufacturing jobs, strengthening American supply chains, and reducing American dependence on Communist China.

Biomanufacturing uses biology to make products at industrial scale, such as new materials and medicines. American companies lead the world in discovering these new products, but all too often, the factories, suppliers, and jobs required to produce them at scale move overseas. Communist China has repeatedly made biomanufacturing a national priority; they now dominate the world’s fermentation capacity.

“America's manufacturing might has been hollowed out for decades,” Congresswoman Dingell said. “This bipartisan bill will strengthen and create good-paying jobs, as well as reduce our reliance on China. I am proud to support this effort to invest in America's workers and ensure we do not cede our competitive edge to our adversaries.”

“Northern Ohio knows that manufacturing is the lifeblood of our economy,” Congressman Latta said. “For far too long, America has pioneered new inventions, only for Communist China to build the facilities—stealing the jobs that come with them. The BEDROCK Act would help reshore that work. This bipartisan legislation would create new opportunities for Ohio workers, strengthen the biomanufacturing supply chain, and make it easier for American manufacturers to produce at home.”

The BEDROCK Act would:

• Designate a senior Department of Commerce official to lead efforts to strengthen U.S. biomanufacturing competitiveness;

• Assess critical supply-chain inputs, domestic production capacity, commercialization barriers, and reliance on China and other foreign adversaries;

• Develop a prioritized action plan and consolidate existing federal resources to address the most significant risks and barriers; and

• Map federal commercialization processes, establish FDA and EPA points of contact, and publish industry-led practices to help companies scale production.